NCT01643083View on ClinicalTrials.gov

Rifaximin for Functional Dyspepsia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Functional Dyspepsia
Interventions
DRUG

Rifaximin

Rifaximin 400mg tid for 2 wk

DRUG

Placebo

Placebo for 2 week

Trial Locations (1)

Unknown

Queen Mary Hospital, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER

NCT01643083 - Rifaximin for Functional Dyspepsia | Biotech Hunter | Biotech Hunter